Article Archive: Reproductive Health
1 July 2010

The report summarizes issues related to the WHO Global Reproductive Health Strategy and its implementation of operationalization. It is not meant to provide a quantitative assessment of the status of sexual and reproductive health in all countries.

General Reports and Articles
Report, Reproductive Health, WHO
J Acquir Immune Defic Syndr
8 July 2010

BACKGROUND: Conflicting data exist regarding the effect of pregnancy on steady-state nevirapine pharmacokinetics (PK), although steady-state nevirapine concentrations during pregnancy have never been characterized in sub-Saharan Africa.

METHODS: This was a longitudinal intensive PK study in Ugandan pregnant women receiving nevirapine-based antiretroviral therapy. Participants underwent intensive 12-hour PK sampling during the second trimester (T2; n = 4), third trimester (T3; n = 15) and 6 weeks postpartum (PP; n = 15). HIV-1 RNA was performed within 2 weeks of each visit. Nevirapine C12 above 3000 ng/mL was classified as optimal based on the suggested value for therapeutic drug monitoring.

RESULTS: The pharmacokinetics of nevirapine were influenced by pregnancy, demonstrated by a 20% reduction in the maximum concentration, minimum concentration (C12), and area under the curve between T3 and PP visits (P = 0.001, P = 0.011 and P = 0.005, respectively). Ten subjects (66.7%) had C12 values <3000 ng/mL during T3. Of these participants, 7 partcipant's C12 concentrations increased to >3000 ng/mL during the PP visit. HIV-1 RNA were <1000 copies per milliliter at T3 and <400 copies per milliliter at PP in all patients.

CONCLUSIONS: Nevirapine exposure was reduced in Ugandan women during their third trimester compared with the same women PP, however, HIV RNA remained <1000 copies per milliliter. The long-term impact of intermittent suboptimal nevirapine concentrations during pregnancy is unknown.
14 October 2010

This policy brief analyzes several key issues and questions on the Obama administration’s new Global Health Initiative (GHI), a six-year, $63 billion proposed effort building on existing disease-specific initiatives to combat HIV, tuberculosis and malaria, while increasing attention to other areas, including maternal and child health, family planning and reproductive health, nutrition, neglected tropical diseases, and the strengthening of underlying health systems.

General Reports and Articles